LCLarry A. Chinitz

Larry A. Chinitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Larry A. Chinitz has a total of 159 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony Aizer

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    14 shared publications
  • Douglas Holmes

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    12 shared publications
  • Lior Jankelson

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    12 shared publications
  • Alexander Kushnir

    Leon H. Charney Division of Cardiology NYU Langone Health New York City New York USA

    9 shared publications
  • Chirag R. Barbhaiya

    Leon H. Charney Division of Cardiology New York University Langone Health New York New York USA

    8 shared publications
  • Leonid Garber

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    8 shared publications

Latest Publications

  • Leadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathy

    by Alexander Kushnir, Mones Aboelatta, Robert Donnino, Douglas Holmes, Chirag R. Barbhaiya, Scott Bernstein, Lior Jankelson, Anthony Aizer, Leonid Garber, Larry A. Chinitz

    Background: Leadless pacemakers (LPs) avoid the lead‐ and pocket‐related complications of transvenous systems, but they pace exclusively from the right ventricle (RV), and chronic RV pacing carries a recognized risk of pacing‐induced cardiomyopathy (PICM). Whether implant location within the RV, a potentially modifiable factor, contributes to this risk has not been established. Methods: Patients undergoing LP implantation with ≥50% RV pacing, pre‐and post‐procedural echocardiograms, and post‐implant 3‐dimensional radiographic imaging were included. All implants targeted the RV septum per manufacturer recommendation. PICM was defined as ≥10% decline in left ventricular ejection fraction (LVEF) to P P <0.001) and discriminated free wall from non‐free wall implantation with an area under the receiver operating characteristic curve (AUC) of 0.85; a QRS duration of 172 ms provided optimal discrimination. Baseline LVEF, baseline QRS duration, and comorbidity burden did not differ between groups. Conclusions: Inadvertent free wall LP implantation is strongly associated with the subsequent development of PICM. Paced QRS duration is a readily available surrogate for implant location, and targeting a paced QRS duration below approximately 172 ms at the time of implant may serve as a practical, non‐invasive check on appropriate septal placement.

  • Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation

    by Joey Junarta, Angela Wang, Eli Reynolds, Aristides Hatzimemos, Pooja Patel, Danielle Shields, Felix Yang, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, et al.

    Background: The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). Methods: We studied consecutive cases of patients with paroxysmal AF undergoing first‐time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1‐year follow‐up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. Results: A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan–Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). Conclusion: PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.

  • The Utility of Higher Pulsed Field Ablation Applications for Atrial Fibrillation Ablation

    by Joey Junarta, Eli Reynolds, Angela Wang, Aristides Hatzimemos, Pooja Patel, Danielle Shields, Felix Yang, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, et al.

    Background: The optimal number of pulsed field ablation (PFA) applications during atrial fibrillation (AF) ablation is unclear. We hypothesized that the number of PFA applications would predict atrial tachyarrhythmia (ATA) recurrence rates. Objective: To determine whether higher numbers of PFA applications would decrease ATA recurrence rates. Methods: We studied cases of patients with AF undergoing first‐time ablation with PFA between 5/6/24 and 10/7/24. All patients underwent pulmonary vein and posterior wall isolation. The primary outcome was ATA recurrence. Additional outcomes included stroke, post‐procedural acute kidney injury (AKI), total procedure time, and major periprocedural complications. Univariable and multivariable analyses were performed to determine if the number of PFA applications predicted ATA recurrence. Results: In a cohort consisting of 177 patients, univariable and multivariable analysis showed that the number of PFA applications split at the smallest quartile (< 57 applications) versus the largest three quartiles (≥ 57 applications) was the strongest predictor of ATA recurrence ( p = 0.03). ATA recurrence at 1 year (29% vs. 8%; p < 0.01) and AF burden on continuous monitor (4% vs. 0%; p < 0.01) was higher with the standard (< 57 applications) vs higher (≥ 57 applications) PFA dose groups. When comparing the standard versus higher PFA dose groups, there was no difference in total procedure time (106 vs. 107 min; p = 0.77), major periprocedural complications (0% vs. 2%; p = 0.33), or post‐procedural AKI (2% vs. 2%; p = 0.69). Conclusion: Increasing number of PFA applications is associated with reduced ATA recurrence. A higher number of PFA applications may decrease ATA recurrence without affecting procedure times or complication rate.

  • Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta‐Analysis

    by Joey Junarta, Daniel M. Simadibrata, Angela Wang, Brian Hsia, Leonid Garber, Chirag R. Barbhaiya, Lior Jankelson, David S. Park, Douglas Holmes, Alexander Kushnir, et al.

    Randomized trials of ethanol infusion into the vein of Marshall (EIVOM) have shown efficacy in preventing atrial fibrillation (AF) recurrence in patients presenting for de novo ablation. The utility of EIVOM in AF patients who present for redo ablation is unclear. This meta‐analysis was reported according to the Preferred Reporting Items for Systematic Review and Meta‐Analyses guidelines. Medline, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. Risk of bias was assessed using the Modified Newcastle‐Ottawa scale. Eligible studies reported outcomes in AF patients with previous ablation who underwent redo catheter ablation (CA) alone vs. combined redo CA and EIVOM. Five observational studies comprising 568 patients were included. When comparing combined redo CA and EIVOM vs. redo CA alone, pooled results showed no difference in freedom from arrhythmia (FFA) in all patients (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.96–1.33), FFA in persistent AF patients only (RR 1.08; 95% CI 0.90–1.29), total procedure time (mean difference −0.59; 95% CI −41.04–39.85), or major periprocedural complications (RR 0.81; 95% CI 0.06–11.64). Patients with AF recurrence after ablation represent a difficult‐to‐treat population. Salvage therapy with combined CA and EIVOM did not improve arrhythmic outcomes compared to CA alone in AF patients who presented for redo ablation.

  • Utility of Very High Output Pace‐Capture Testing for Posterior Wall Isolation in Patients With Persistent Atrial Fibrillation

    by Brian Hsia, Jordan Liebman, Leonid Garber, Felix Yang, Michael Spinelli, Yury Malyshev, Alexander Kushnir, Lior Jankelson, Scott Bernstein, David Park, et al.

    Background: Pulmonary vein isolation (PVI) and posterior wall isolation (PWI) are frequently used in the treatment of persistent atrial fibrillation (AF). Minimal data support adjunct PWI, possibly due to lack of durability via epicardial reconnections. Objective: To determine the impact of very high output PW pace‐capture testing in patients with persistent AF on AF/AT recurrence. Methods: We performed a retrospective study of consecutive patients who underwent radiofrequency ablation for persistent AF and received PVI and PWI, as well as a cavotricuspid isthmus line (CTI). After the creation of three linear PW lesions (roof, carina‐to‐carina, and inferior PV levels), pace‐capture testing was performed on the PW. The first cohort confirmed PWI using 10 mA at 2 ms (10 × 2) to pace capture. Sequentially, the second cohort utilized 20 mA at 10 ms (20 × 10). If the PW was captured, additional lesions were performed. Patients were excluded if additional lesion sets beyond PVI, PWI, and CTI were performed. Results: A total of 232 patients were included. Of these, 129 (56%) patients were in the 20 × 10 group, and 103 (44%) patients were in the 10 × 2 group. The two groups did not differ in age, sex, proportion of comorbidities, presenting rhythm, left ventricular ejection fraction, or left atrial size. Despite the increase in procedure time and lesion number, in the time‐to‐event analysis, patients in the 20 × 10 group experienced recurrent AF/AT more frequently than those in the 10 × 2 group (log rank p = 0.01). Conclusion: Testing PWI in persistent AF with pace capture at 20 mA at 10 ms did not improve freedom from arrhythmia and may paradoxically be associated with harm. Our findings question whether PWI, regardless of durability, is effective in treating persistent AF.

  • Open Access

    Left bundle branch area stylet-driven lead: Performance, safety, and quality of life at 12 months after implant (the BIO-CONDUCT investigational device exemption study)

    by Christopher F. Liu, Karthik Venkatesh Prasad, Antonio Moretta, Matthew A. Goldstein, Pugazhendhi Vijayaraman, Marye Gleva, Larry A. Chinitz

  • To Ablate or Wait?

    by John Santucci, Larry A. Chinitz

  • Electrogram Frequency Analysis and Isochronal Activation Surface Area Mapping for Ablation of Premature Ventricular Contractions

    by Michael A. Hoffer‐Hawlik, Alyna Pradhan, Elizabeth Rosinski, Lior Jankelson, Alexander Kushnir, Leonid Garber, Douglas Holmes, Anthony Aizer, Larry A. Chinitz, Chirag R. Barbhaiya

    Introduction: A lower frequency early electrogram (EGM) or broad area of early activation during premature ventricular contraction (PVC) mapping may be associated with a PVC origin in an opposing chamber or deep within the mapped surface. The utility of quantifying EGM frequency at early activation sites and isochronal activated surface area (IASA) is unclear. Our study aimed to investigate the utility of EGM frequency analysis and IASA mapping to complement activation mapping during PVC ablation. Methods: High density PVC activation and IASA maps were created using a multi‐electrode mapping catheter in 25 patients undergoing PVC ablation. EGMs in early activation regions were retrospectively studied. IASAs in each mapped chamber were analyzed. Results: Ablation success was achieved in 18 of 25 (72%) patients. Ablation was successful in all patients with EGM frequency > 325 Hz (local activation time (LAT) range 28–54 ms) and in all patients with pre‐QRS LAT > 40 ms (EGM frequency range 127–563 Hz). In patients with pre‐QRS LAT < 40 ms and EGM frequency < 325 Hz, ablation was successful in 9 of 16 cases (56%). Mean IASA mapped within 10 ms was smaller at successful ablation sites compared to opposing chambers (0.33 vs 0.95 cm 2 , p = 0.02). All ablation in chambers with IASA > 1.5 cm 2 within 10 ms was unsuccessful. Conclusion: Higher EGM frequency and smaller IASA were associated with successful ablation of PVCs. Ablation at sites with EGM frequency > 325 Hz was successful in all patients. The utility of identifying higher frequency EGMs at early activation sites requires further study.

  • Vein of Marshall Ethanol Ablation as a Strategy for Recurrent Persistent Atrial Fibrillation

    by Brian C. Hsia, Peter Zhang, Joey Junarta, Leonid Garber, Felix Yang, Michael Spinelli, Yury Malyshev, Alexander Kushnir, Lior Jankelson, Scott Bernstein, et al.

    Background: Vein of Marshall (VOM) ethanol ablation is effective in preventing recurrence in patients with persistent atrial fibrillation (AF) as a de novo strategy. There is minimal data on its use in recurrent AF. Objective: We investigated the efficacy of VOM ethanol ablation for recurrence despite initial AF ablation. Methods: Retrospective analysis was performed of persistent AF patients who underwent repeat ablation after an initial ablation for persistent AF. All patients had pulmonary vein isolation (PVI), posterior wall isolation (PWI), and cavotricuspid isthmus (CTI) during their previous ablation(s). At redo ablation, controls underwent confirmation and completion of previous ablation steps, substrate modification, and a search for non‐PV triggers. Cases had additional VOM ethanol ablation combined with mitral isthmus ablation. Results: One hundred and seven patients (49 VOM, 60 control) were included. There was no difference in AF recurrence at 1‐year comparing VOM patients (47%) and controls (38%), ( p = 0.39). Within the VOM group, the mean AF burden decreased from 38% preablation to 10% 12‐months post ( p = 0.003). The proportion of recurrent persistent AF decreased from 65% preablation to 26% post ( p = 0.004). There was no significant difference in reduction in AF burden or proportion of recurrent persistent AF when comparing VOM cases and controls. Six percent of VOM patients developed intraprocedural left atrial appendage (LAA) isolation. Conclusions: In patients with previous PVI, PWI, and CTI ablation, VOM ethanol ablation did not demonstrate a reduction in AF recurrence or burden when compared with a strategy of substrate modification and trigger ablation alone and increases the risk of LAA isolation.